Drug infusion into the belly for stomach or colorectal cancer that has spread
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called rmhTNF that is put directly into the abdomen (the belly area) to help prevent or treat cancer that has spread there (called peritoneal metastasis) and to reduce fluid buildup (called malignant ascites). The goal is to see if this treatment can help control the cancer and improve symptoms in people with advanced stomach or colorectal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have stomach or colorectal (colon/rectum) cancer that is advanced, has spread, or has come back after treatment
- You are able to take care of yourself (performing daily tasks without needing to lie down most of the day)
- Your blood counts (white cells, platelets, hemoglobin) and liver/kidney function have to be within a certain healthy range
- You are not allergic to TNF, biological products, or penicillin
- You are willing to sign a consent form for this treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining standard chemotherapy and immunotherapy (tirelizumab) with heated chemotherapy given directly into the belly. It aims to treat stomach cancer that has spread to the abdominal lining, and may help shrink or control the cancer.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This early-phase trial tests a new type of immune cell therapy (TCRx T cells) for advanced stomach cancer that has not responded to standard chemotherapy. The goal is to see if these specially engineered cells can help your body fight the cancer.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial studies a combination treatment for stomach cancer that has spread to the lining of the abdomen. It uses a special way to deliver heated chemotherapy directly into the abdomen, along with an immunotherapy drug that helps your immune system attack the cancer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.